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Background: To achieve optimal cytoreduction for advanced-stage ovarian cancer, modified posterior exenteration
is the most frequently performed bowel surgery. We assessed the extents of tumor spreading in the rectosigmoid
wall and pelvic side wall in modified posterior exenteration specimens during primary debulking surgery (PDS) and
interval debulking surgery (IDS) following neoadjuvant chemotherapy, and compared the validity of selecting this
surgical procedure in the patients undergoing PDS with that in the patients undergoing IDS.
Methods: Clinicopathological data from consecutive patients who had undergone a modified posterior
exenteration for primary ovarian, tubal, and peritoneal cancer at our institution between April 2008 and March 2013
was retrospectively reviewed.
Results: A total of 75 patients (38 in PDS and 37 in IDS) were included in this study. Tumor involvement of the
rectosigmoid was histopathologically confirmed in 65 % of the specimens. Though the extent of tumor spreading
in the rectosigmoid was deeper in PDS than in IDS, the frequency of tumor involvement of the rectosigmoid in
patients who had undergone modified posterior exenteration during PDS was equivalent to that in the IDS group.
Lateral tumor spreading to the side wall(s) was histopathologically confirmed in 53 % of the patients in whom a
pelvic side wall resection had been performed.
Conclusions: During both PDS and IDS for ovarian cancer presenting with tumor involvement of the cul-de-sac,
close inspection and palpation by gynecologic oncologists may enable the extent of tumor spreading in the pelvis
to be estimated, enabling valid decisions as to whether an en bloc resection of the pelvic tumors together with the
rectosigmoid and the pelvic side wall might or might not be appropriate.
Keywords: Ovarian cancer, Modified posterior exenteration, Histopathology, Primary debulking surgery, Interval
debulking surgeryBackground
Effective cytoreduction at the time of primary surgery
has been identified as the most important prognostic
factor in the management of advanced-stage ovarian
cancer [1, 2]. The goal of cytoreductive surgery is to ob-
tain a macroscopic complete resection of the disease;
such surgery is now considered to be the “real” optimal
debulking surgery [3, 4]. Primary debulking surgery* Correspondence: kazuyosikato@gmail.com
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treatment for advanced-stage ovarian cancer. However,
for those unable to tolerate PDS or with an initial dis-
ease that is too extensive for optimal debulking, interval
debulking surgery (IDS) following neoadjuvant chemo-
therapy (NAC) is considered to be a valuable alternative
option for PDS. The usefulness of this strategy has been
confirmed in a recent randomized trial performed by the
European Organisation for Research and Treatment of
Cancer Gynaecological Cancer Group and National Can-
cer Institute of Canada Clinical Trials Group; comparing
PDS with IDS reported that progression-free survival
and overall survival were similar in both groups [5].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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to the female pelvic organs and its frequent involvement
in ovarian cancer, rectosigmoid resection is the most fre-
quently performed bowel surgery to achieve optimal
cytoreduction [6]. Many investigators have studied the
value of modified posterior exenteration, also known as
low anterior en bloc resection or radical oophorectomy,
during debulking surgery for ovarian cancer [6–9]. Al-
though modified posterior exenteration has acceptable
morbidity and mortality rates, anastomotic leakage after
rectosigmoid resection remains a life-threatening poten-
tial complication [10].
If the tumor is suspected of having infiltrated the pel-
vic side wall, an en bloc resection of the pelvic side
wall(s) together with the uterus, adnexa, and rectosig-
moid should be performed to achieve optimal cytore-
duction and to complete the surgical procedure safely
[6, 11]. This surgical procedure is accompanied by the
sacrifice of the ipsilateral autonomic nerves, resulting
in postoperative bladder dysfunction to some extent
[12]. In addition, as a pelvic side wall resection involves
the removal of connective tissue containing lymphatic
tissue around the internal iliac vessels and/or the in-
ternal iliac vessels themselves, possibly resulting in se-
vere bleeding.
In ovarian cancer patients with tumor involvement of
the cul-de-sac in whom a modified posterior exenter-
ation with or without pelvic side wall resection has been
performed, the histopathologic evaluation of tumor
spreading is useful for evaluating the validity of the se-
lection of this type of surgery. In the present study, we
assessed the extents of tumor spreading in the rectosig-
moid wall and pelvic side wall in modified posterior exen-
teration specimens from patients with primary ovarian,
tubal, and peritoneal cancer during PDS and IDS. Then,
we compared the validity of selecting this surgical proced-
ure in the patients undergoing PDS with that in the pa-
tients undergoing IDS.
Methods
All consecutive patients who underwent modified pos-
terior exenteration as part of debulking surgery for pri-
mary ovarian, tubal, and peritoneal cancer at the Chiba
University Hospital between April 2008 and March 2013
were evaluated for inclusion in this study. All the surgical
procedures were performed by gynecologic oncologists
working at our institution. We performed a laparotomy as
an up-front surgery in all the cases with advanced-stage
ovarian cancer. When PDS was thought to be possible, we
then performed cytoreductive surgery. In patients with
metastatic disease that was initially too extensive for opti-
mal debulking, the abdominal wall was closed and NAC
followed by IDS was considered. During modified poster-
ior exenteration, preservation of the pelvic autonomicnerves on both sides was attempted whenever possible.
However, an en bloc resection of the pelvic side wall(s)
together with the uterus, adnexa, and rectosigmoid,
resulting in the unilateral or bilateral sacrifice of the
pelvic autonomic nerves, was necessary in cases with
suspected tumor spreading in the pelvic side wall(s).
The type of surgery was chosen by gynecologic oncolo-
gists depending upon the intraoperative findings of the
disease in each patient. The tumor spreading was veri-
fied by inspection and manual palpation during the op-
eration as well as by preoperative findings using various
radiologic modalities including magnetic resonance im-
aging (MRI). Decisions regarding the proximal and dis-
tal resection sites of the rectosigmoid were made based
on these findings. During IDS following NAC, if the
masses were palpable under the pelvic peritoneum or
the visceral serous membrane appeared to be intact, we
made efforts to remove all of these tissues. Our surgical
procedure for a modified posterior exenteration has
been previously described [12]. Regarding the extent of
the pelvic side wall resections, our technique corre-
sponds to that of laterally extended endopelvic resec-
tion advocated by Höckel [11]. If the primary and
metastatic tumors in the cul-de-sac had invaded lat-
erally and posteriorly into the uterosacral ligament and
the inferior hypogastric plexus was to be sacrificed, the
cardinal ligament and the posterior leaf of the vesicou-
terine ligament were divided. In cases with tumor
spreading in the deep retroperitoneal space, the lateral
resection line is formed by following the lumbosacral
nerve plexus, piriformis muscle, internal obturator
muscle, and levator ani muscle. During surgery for
these patients, an ipsilateral pelvic lymphadenectomy
and a division of the internal iliac vessels were per-
formed when the pelvic side wall resection was accom-
plished. Consequently, in surgical specimens of a
modified posterior exenteration with pelvic side wall re-
section, tumor spreading in the side wall(s) was sur-
rounded with the parietal pelvis tissue (Fig. 1).
The following data were retrieved from the patients’
medical records: patient age, primary site of disease, clin-
ical stage, largest tumor size at the time of surgery, timing
of surgery (PDS or IDS), type of surgery (modified poster-
ior exenteration without pelvic side wall resection, with
unilateral pelvic side wall resection, or bilateral pelvic side
wall resection), final histopathologic results, and follow-up
data. With respect to the histopathology, all the available
information, including the histopathologic subtype of the
tumor, the extent of tumor spreading in the rectosigmoid
and pelvic side walls, and the margin status in the speci-
men, was recorded. Statistical analyses were performed
using the Wilcoxon signed-rank test and the Fisher exact
test. A value of P less than 0.05 was considered statistically
significant.
Fig. 1 Surgical specimen of a posterior exenteration with the left pelvic side wall resection. a Ventral view of an en bloc resection specimen of
the pelvic side wall tissue together with the uterus, adnexa, rectosigmoid, and ileum. The specimen included intact parietal pelvis tissue around
the tumor spreading in the deep retroperitoneal space (arrowheads). b Cut surface of the specimen. Tumor infiltration into the mucosa of the
rectal wall can be seen (white arrows). The framed rectangle corresponds to the area shown in Fig. 1c. c Histopathologic section of the specimen
showed tumor infiltration into the skeletal muscle (hematoxylin and eosin staining, ×20)
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Review Board of the Chiba University School of Medicine.
Results
During the 5-year study period, modified posterior exen-
teration was performed in 75 patients with primary ovar-
ian, tubal, and peritoneal cancer at the time of initial
therapy. The clinical and tumor characteristics of all the
patients in this series are shown in Table 1. PDS was
performed in 38 patients (51 %), and IDS was performed
in 37 patients (49 %). Colorectal anastomosis using a cir-
cular stapling device or a hand-sewn technique was per-
formed in 69 patients (92 %). Hartmann’s operation was
performed in five patients, and posterior pelvic exenter-
ation accompanied by the resection of the vaginal pos-
terior wall was performed in one. Modified posterior
exenteration without pelvic side wall resection was per-
formed in 58 patients (77 %). Modified posterior exen-
teration with unilateral and bilateral pelvic side wall
resection was performed in 16 patients (21 %) and 1 pa-
tient, respectively. Among the patients in whom a modi-
fied posterior exenteration without pelvic side wall
resection was performed, a pelvic lymphadenectomy was
performed in 47 patients. As mentioned above, a pelvic
lymphadenectomy was performed naturally in all 17 pa-
tients in whom a modified posterior exenteration with
pelvic side wall resection was performed. Sixty-nine pa-
tients (92 %) had no visible tumor after surgery, and six
other patients had residual tumors with a maximal
diameter of <0.5 cm. None of the patients had macro-
scopic residual tumor in the pelvis.Table 2 shows the differences in the extent of tumor
spreading in the rectosigmoid wall between the patients
who underwent a modified posterior exenteration in the
PDS group and those in the IDS group. Of the 38 pa-
tients who underwent PDS, the resection margins in the
specimen were positive in two patients (5 %); both pa-
tients had positive distal (anal side) margins in the recto-
sigmoid because of tumor invasion in the lymphovascular
space. Of the 37 patients who had undergone IDS, two pa-
tients (5 %) had positive resection margins; the distal mar-
gin in the rectosigmoid in one patient, and the proximal
(oral side) margin in the rectosigmoid in the other patient.
Two other patients (5 %) had close resection margins,
which were defined as surgical margins within 5 mm of
the tumor spread; the distal margin in the rectosigmoid in
one patient, and the proximal margin in the rectosigmoid
in the other patient.
Table 3 shows the differences in the extent of tumor
spreading in the pelvic side wall between the patients
who underwent a modified posterior exenteration with
pelvic side wall resection in the PDS group and those in
the IDS group. None of the patients included in this
study had positive or close circumferential or vaginal
margins.
The median duration of the follow-up period was 30.1
months (range, 6.2–74.5 months). Overall, 25 recurrences
(33 %), 4 pelvic recurrences (5 %), and 12 deaths (16 %)
occurred during the follow-up period. One of two patients
who underwent PDS with positive resection margins in
the rectosigmoid had multiple bone metastases as a recur-
rence. Among four patients who underwent IDS with
Table 1 Patient and tumor characteristics
Characteristics Result
Age, median (range), y 60 (31–83)
Diagnosis and stage
















Clear cell 8 (11)
Endometrioid 7 (9)
Others 12 (16)
Largest size of pelvic tumor at surgery, n (%)
<50 mm 22 (29)
50–100 mm 18 (24)
>100 mm 35 (47)
Pelvic lymph node involvement, n (%)
Positive 26 (35)
Negative 38 (51)
No pelvic lymph nodes found 11 (15)
Table 2 Differences in the extent of tumor spreading in the
rectosigmoid wall between patients who underwent a modified








Rectosigmoid wall involvement 0.939
Positive 25 24
Depth of tumor invasion 0.012
Mucosal or submucosal layer 7 3
Muscular layer 11 5
Serosal layer 7 16
Negative 13 13
Factor in rectosigmoid adhesion 0.706
Tumor involvement of the mesocolon 2 1
Tumor involvement of the peritoneum
of the cul-de-sac
4 2
Fibrosis, necrosis, and/or granulation 3 8
Endometriosis 3 1
No histopathologic finding 1 1
PDS primary debulking surgery, IDS interval debulking surgery after
neoadjuvant chemotherapy
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one patient had a pelvic recurrence and additional two pa-
tients had distant metastases as a recurrence during this
period.
Discussion
The present study evaluated the histopathologic results
of tumor spreading in surgical specimens obtained dur-
ing modified posterior exenteration for primary ovarian
cancer. Our results indicate that during surgery for ovar-
ian cancer presenting with tumor involvement of the
cul-de-sac, close inspection and palpation by gynecologic
oncologists can enable the extent of tumor spreading in
the pelvis to be estimated in most cases, enabling valid
decisions as to whether an en bloc resection of the pelvic
tumors together with the rectosigmoid and the pelvic
side wall might or might not be appropriate.Tumor involvement of the rectosigmoid wall was
histopathologically confirmed in 65 % of the cases. A
previous study reported that in 73 % of patients with
suspected infiltration of the cul-de-sac (bulky tumor, dis-
seminated tumor spread), the rectosigmoid wall was
histopathologically infiltrated by the tumor [13]. They
argued that in the majority of ovarian cancer patients
with intraoperatively suspected cul-de-sac infiltration,
residual tumor is likely to be present in the wall of the
rectosigmoid if only deperitonealization, and no en bloc
resection of the uterus and rectosigmoid, is performed.
In this study, histopathologic examinations suggested
that in cases without tumor spreading in the rectosig-
moid or cul-de-sac, a modified posterior exenteration
was performed because of fibrosis, necrosis, granulation,
and/or endometriosis. Macroscopic inspection may over-
estimate the tumor involvement in such cases. MRI is an
anatomic, high-resolution imaging modality that is
widely used to guide the management of patients with
ovarian cancer [14, 15]. Of course, our surgical decisions
were made based not only on macroscopic inspection,
but also on dynamic contrast-enhanced and diffusion-
weighted MRI findings. The extent of tumor spreading
in the rectosigmoid wall was deeper in the patients who
underwent PDS than in those who underwent IDS. This
difference was likely due to the effect of neoadjuvant
chemotherapy before surgery, which reduced the tumor
volume and spreading. However, a histopathologic evalu-
ation showed that the frequency of tumor involvement
of the rectosigmoid in patients who have undergone
Table 3 Differences in the extent of tumor spreading in the
pelvic side wall between patients who underwent a modified
posterior exenteration with pelvic side wall resection in the PDS






Pelvic side wall involvement 0.354
Positive 8 2
Extent of tumor spread 0.435
Parametrium and/or paracolpium 8 2




Internal iliac vessels 0 0
Levator ani muscle 1 0
Negative 4 3
Pelvic lymph node involvement 1.000
Positive 5 2
Negative 7 3
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lent to that in the patients who have undergone modi-
fied posterior exenteration during IDS.
In this study, histopathologic examinations showed
that the resection margins in the rectosigmoid wall were
positive in 5 % of the patients who had undergone PDS,
and were positive in 5 % and close (surgical margins ≤5
mm) in an additional 5 % of the patients who had under-
gone IDS. The lower segment of the rectum lies retro-
peritoneally. In the greater part of ovarian cancer cases
presenting with a confluent tumor in the cul-de-sac, the
lower segment of the rectum is free of tumor, since ovar-
ian cancer grows along the peritoneal lining. Despite an
intent to remove all visible and palpable tumors, how-
ever, there are some cases in which the resection mar-
gins are microscopically positive. In PDS, tumor-free
resection margins (R0) are associated with a significant
reduction in pelvic recurrences among ovarian cancer
patients undergoing modified posterior exenteration
[13]. It is not evident that all attempts should be made
to achieve an R0 status during IDS. In the current series,
the rate of positive resection margins in the rectosig-
moid wall among the patients undergoing PDS was
equivalent to that in patients undergoing IDS. Half of
the patients with positive or close resection margins in
the rectosigmoid experienced distant recurrence. This
result may have been due to the wide-spread of tumor
reflecting in positive or close resection margin in the
rectosigmoid and microscopic residual disease remaining
in extra-pelvic areas.
Gynecologic oncologists occasionally encounter cases
with tumor spreading in the deep retroperitoneal space.Not only to secure negative surgical margins but to ac-
complish the procedures safely and securely for cases, the
pelvic side wall resection is needed for these cases. In the
current series, tumor involvement of the parametrium
and/or the parametrium surrounding the uterus and va-
gina was frequent (75 % of the patients in the PDS group
and 40 % of the patients in the IDS group). Lateral tumor
spreading to the cardinal ligament and/or deep retroperi-
toneal space was histopathologically confirmed in 25 % of
the patients in the PDS group and in 20 % of the patients
in the IDS group. In addition, tumor spreading beyond
the deep retroperitoneal space to the levator ani muscle
was confirmed in only one patient in whom a pelvic side
wall resection had been performed. Similarly, the previous
study showed that though infiltration of the parametrium
and paracolpium frequently occurred in patients who
underwent a modified posterior exenteration with pelvic
side wall resection, tumor involvement of the parietal pel-
vis, including the internal iliac vessels, levator ani muscle,
and internal obturator muscle, was rare [11, 16]. Although
nerve-sparing modified posterior exenteration on at least
one side is useful, pelvic side wall resection results in the
sacrifice of the pelvic autonomic nerves to some extent
[12]. The results of this study showing that none of the pa-
tients with pelvic side wall resection had positive or close
circumferential margins in the specimens suggest the val-
idity of this surgery.
From the results of this study, the presence of cancer
cells within desmoplastic stroma was histopathologically
demonstrated in the palpable masses under the pelvic
peritoneum, and the visceral serous membrane appeared
to be intact during IDS in many cases. The use of NAC
before surgery induces tumor necrosis, fibrosis, macro-
phage infiltration, and tumor-induced inflammation in
the peritoneal cavity. Then, residual cancer cells remain
in deep visceral and retroperitoneal tissue. There is a re-
port that among advanced ovarian cancer patients with
residual disease of <1 cm, the size of the viable tumor in
the operative specimens was inversely correlated with
progression-free survival and overall survival [17]. We
supposed that the removal of as many palpable masses
under the peritoneum as necessary was feasible. A re-
cent report has suggested that microscopically carcin-
omatous areas often have a benign visual appearance
after neoadjuvant chemotherapy in advanced ovarian
cancer [18]. Accordingly, intraoperative macroscopic
evaluation of the extent of the tumor is more accurate in
PDS than in IDS. It was stated that the removal of all
peritoneal surfaces affected at the time of diagnosis
should be considered in IDS. However, this approach
would lead to more extensive debulking operations, with
the consequent loss of some of the benefits that are
presently linked with IDS. Thus, a study investigating
whether the resection of sites involved by primary and
Kato et al. World Journal of Surgical Oncology  (2015) 13:230 Page 6 of 6metastatic tumors at the time of diagnosis are associated
with a higher survival should be performed in larger
prospective trials in the future.
There are some limitations that must be considered
when interpreting these data. First, this was a retrospect-
ive study design. Second, the number of the patients
whom pelvic side wall resection had been performed
was small and further studies with the long follow-up
period are needed to confirm the efficacy of this surgical
procedure. Despite these limitations, study strengths
consist of a report from one institution where the treat-
ment approaches were not changed throughout the in-
clusion period.
Conclusions
The evaluation of whether the tumor involves the rec-
tosigmoid wall and the pelvic side wall is critical, based
on physical investigations performed during the modi-
fied posterior exenteration with or without pelvic side
wall resection. As a close inspection and palpation by
gynecologic oncologists to estimate the extent of tumor
spreading in the pelvis seems to be appropriate, this
procedure might be achieved under a conventional
laparotomy. This approach may also be useful for the
cytoreduction of the upper-abdominal spreading of dis-
ease in cases of advanced-stage ovarian cancer.
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